SAN FRANCISCO, Nov. 6 – Nanogen completed internal validation of a DNA-based  research protocol for the MTHFR mutation to use on the NanoChip Molecular Biology Workstation, the company announced Tuesday.

MTHFR is associated with cardiovascular disease and the pathology of thrombosis. Protocol users will have the option to further develop and validate the protocols for internal use, the company said.

This is the fourth DNA-based research protocol that the San Diego-based company has internally validated for use on the NanoChip Molecular Biology Workstation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

Wired reports that 23andMe is trying to bolster its outside collaborations.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.